Approval
Aoruite Wins Hormone Therapy Approval
China's National Medical Products Administration approved Yangzhou Aoruite's estradiol 0.5 mg and dydrogesterone 2.5 mg tablets for postmenopausal hormone replacement therapy. The approval expands Aoruite's women's health portfolio to include a continuous combined low-dose regimen.
The company reported approximately RMB 8.4875 million in unaudited cumulative development spending. Abbott's original product was approved in China in 2024.
The announcement cites approximately RMB 5.0624 million in Chinese hospital sales for estradiol and dydrogesterone tablets in 2025.
Written by Gosset from public sources. Source types: SEC/exchange filing. Sources are available to Gosset users. Log in to see them.